Patient Name: RUPALI PAGARE	Date: 15/11/2024
Patient Id: 7636	Age/Sex: 32 Years / FEMALE
Ref Phy: DR. SARDA	Address :

ULTRASONOGRAPHY OF ABDOMEN AND PELVIS

<u>LIVER</u>: The liver is normal in size It measures 13.4 cm, shape, position, echogenicity and echotexture. Normal respiratory movements are seen. No focal solid or cystic mass lesion is noted.

<u>BILIARY SYSTEM</u>: Gall bladder shows normal physiological distention. No mural mass or calculus is noted. There is no evidence of pericholecystic fluid. CBD and intra hepatic biliary radicles show normal caliber.

<u>PANCREAS:</u> The pancreas is normal in size, shape, echogenicity and echo texture. No solid or cystic mass lesion is noted. Pancreatic duct is not dilated.

SPLEEN: The spleen is normal in size It measures 9.3 cm, shape, position, echogenicity and echotexture. No focal mass lesion is noted.

KIDNEYS: Right kidney measures 9.5 x 3.3 cm. Left kidney measures 10.5 x 3.5 cm. Both kidneys are normal in size, shape, position, echogenecity and echotexture. Normal corticomedullary differentiation is noted. No focal solid or cystic mass lesion or any calculus is seen. Pelvicalyceal systems on both sides are normal.

URINARY BLADDER: The urinary bladder shows physiological distention. It shows normal wall thickness. No calculus or mass lesion is seen.

<u>UTERUS</u>: The uterus is anteverted. It measures $59.5 \times 43.1 \times 35.9 \text{ mm}$. It is normal in size, shape, position, echogenecity and echotexture. There is no focal mass lesion in uterus. Endometrium measures 12.8 mm.

<u>ADNEXA</u>: Right ovary measures $2.9 \times 1.2 \times 2.4 \text{ cm}$. Volume is 4.5 cc Left ovary measures $2.1 \times 1.2 \times 2.1 \text{ cm}$. Volume is 2.7 cc. Both ovaries are normal in size, shape, echogenecity and echotexture. There is no focal solid or cystic mass lesion in it. No appreciable other adnexal space occupying lesion is noted.

<u>OTHERS</u>: There is no free or loculated fluid collection in abdomen or pelvis. No significant lymphadenopathy is noted.

IMPRESSION:


No significant sonographic abnormality noted.



Fellow in MSK imaging



Name:RUPALI PAGARE Age:32 Y Sex:Female RefDr:Sarda Date:15-Nov-2024



Patient Name: RUPALI PAGARE	Date: 15/11/2024
Patient Id: 7642	Age/Sex: 32 Years / FEMALE
Ref Phy: DR. SARDA	Address :

RADIOGRAPH OF CHEST PA VIEW

Findings:

Both the lung fields are clear.

The broncho vascular markings are appears normal.

The hilar shadows are appears normal.

Both Cardiophrenic and Costophrenic angles are clear.

The Cardiac silhoutte is within normal limits.

Aortic shadow is normal.

Both domes of diaphragms are normal.

The visualised bony thorax is normal.

Impression:


No significant abnormality noted in X-ray chest.



DR AMEY S. JAJU, MBBS, DNB RADIOLOGY Fellow in MSK imaging

ANUSHREE SONOGRAPHY & X-RAY CENTRE

Name:Rupali Pagare Age:32 Y Sex:Female RefDr:Dr. Sarda Date:15-Nov-2024





CENTRE FOR DIABETES & SELF CARE

PATIENT NAME: MRS. RUPALI PAGARE

AGE:32YR. SEX: FEMALE

REF BY: MEDIWHEEL

DATE:15/11/2024

PAP SMEAR

Source : Cervical Smear

General Characterization: Smear shows plenty of superficial squamous epithelial cells, sparse

inflammatory cells. No e/o any abnormal cells No e/o dysplasia in present smear study.

Interpretation: Mild inflammatory smear.

Dr.S R. SARDA
M.D Rep. No.58462
M.D Rep. No.58462
DR.SAMPAT SARDA Julius Rood. Au. angabad
M.D.(PATHOLOGY)

SARDA

CENTRE FOR DIABETES & SELF CARE

15-11-24,

mrs. Rupali Pagase has undergene dentae check inp in my clinic. Her dentar hygiene is good.

Souch.

DP SONALI LOHIYA

Reg No a 0450 Fireball Nethaleys & China China faire Road Accordance



SARDA

CENTRE FOR DIABETES & SELF CARE

Name My Rupoli Pogare Address Bowe of Boroka Date: 15/11/24 Age/Sex 32 401 female

OPHTHALMIC EXAMINATION REPORT

T.	Right Eye	<u>Left eye</u>	
Vision Distant	6/15-1.75	N 616 2-1-75	
Vision Near	N6	N6	
Anterior segment	NAD	NAD	
Pupils	NSRTL	NSRTL	
Lens	clear	clear	
Tension	Normal	Normal	
Fundus:-	Over Dis wm crovz	epo-3	
Colour Vision	Home	wormen,	

Impression: (BE) myopic Astynatin.

Rest wining wound limit

& oral

SARDA

CENTRE FOR DIABETES & SELF CARE

Nave Mr. Rappoli Waman Pagare

age 3241 / f

wh 58.7 by

BP. 12017out

PA- soll

PIS- up & vagin (B)

PV- Ut Av. NS. mobile


PAP Smean taken

Sent-for HPR

Ansevour

Or, Mrs. A.S.Navandar MBBS Reg. No. 38439 Aurangabad





CENTRE FOR DIABETES & SELFCARE 4, Vyankatesh Neger, Jeins Road, Aurangabad. Ph.: (0240) 2333851, 2334856.	Age: 3 200/ f	Blood Pressure:		© ©	0	0	0		Dr. A. S. SANDA M. Der N. P. P. C. R. B. S. SELT CARE
CENTRE FOR DIABETES & SELFCARE 4, Vyankatesh Neger, Jeins Road, Aurangabad. Ph.: (0240) 233385	Name: MSS. Rupale Pupere	(Cms) :		ORS. Complex :	T. Weve :	QT Interval:	PR Interval	men	Dr. A. M. DEC.
FOR DIAL	CLINICAL SUMMARY:	Height (Cms) :	198:	5. Beergeand	Me	8	0	Jation :	hapals
ENTRE	lame: MS	Weight:	ECG FINDINGS :	Rate:	Mechanism :	Axis:	P. Wave:	Recommendation :	Date

ASIAN HOSPITAL MOTTWALKSOURRE AURANGABAD

Station Telanhone

EXERCISE STRESS TEST REPORT

Patient Name: Pagare , Rupali Patient ID: 03382 Height: 162 ger Weight: 58 kg

DOB: 05.06,1992 Age: 32yra Gender: Fertiale Ruce: Asinn

Study Date: 15.11.2024 Test Type: # Protocol: BRUCE

Referring Physician: -Attending Physician: Dr.Deorgo Phenge Technician: --

Medicationic

Medical History:

Reason for Exercise Test:

Exercise Test Summary

Phase Name	Stage Name	Time in Stage	Speed (mph)	Grade (%)	HR (bpm)	BP (mmHg)	Comment
PRETEST	SUPINE	00:38	0.00	0.00	125	120/80	
	STANDING HYPERV.	00:04 00:42	0.00	0.00	122		
EXERCISE	STAGE 1 STAGE 2	03:00	1.70 2.50	10,00	166 179	130/80	
RECOVERY	STAGE 3	61:07 04:04	3.40 0.00	14,00 0.00	193 120	150/80	

The patient exercised according to the BRUCE for 7:06 min;s, achieving a work level of Max. METS: 10.10. The resting heart rate of 130 bpm rose to a maximal heart rate of 193 bpm. This value represents 102 % of the maximal, age-predicted heart rate. The resting blood pressure of 120/80 mmHg, rose to a maximum blood pressure of 150/80 mmHg. The exercise test was stopped due to Dysphuli.

Interpretation

Summary: Resting ECG: normal.

Functional Capacity: normal.

HR Response to Exercise: appropriate.

BP Response to Exercise: normal resting BP - appropriate response

Chest Pain: none. Arrhythmias: none. ST Changes; none,

Overall impression: Normal stress test.

Conclusions

Exercise of brace protocol for 07:06min.

Target heart rate achieved


No Angina/Arrythmias No Significant Increase in ST-T Changes as Compare to Baseline.


Test is Negative for Induced ischemia


0.00	The Land					
Phy	circing	2111111111			Feehnicins	
E-YIC	STATES		 	 		





wrao Thenge


























Page 1	8	orao Then	fD: Dr.De	Attending ND: Dr.Doorso Thense			Unconfirmed	Unex			(C) (C) (A)	OE CardioSoft V6 73 (2)
						Y .						
		6.8 8.8	9.6	18900	150%0	126	13 E	0,00	0.00	04.04	DI MILI	RECOVERY
		išės	000	21580	130/80	179	24.5	1200	. V I S	03,00 03,00	STAGE:	EXEMISE
		-0.85 -0.85 -0.85		15000	129/80	55	1.0	0.00	0.00	00:38	SUMMAN	PRETEST
	Common	ST Level (III mm)	(/min)	RPP VE (mnHg*bpm t/min)	(mmHg) 1	(dpm)	(METS)	Orade (%)	Speed (mph)	Time in Stage	Stage Name	Phase Name
No Anglist Arrythmas No Significant Increase in ST-T Changes as Compare to Baseline. Test is Negative for Induced techemia	ng nSt-TOa	icani Inco	No Signif	No Anglin/Arrythmics No Significant Baseline. Test is Negative for Induced ischemia	No Angin Baseline Test is Ne							
	07.06min.	otocol for	if bruce pr	BI Exercise	Conclusion Carnet her							
Summary: Resting ECC: normal. Functional Capacity: normal. HR Response to Exercise: appropriate. BP Response to Exercise: normal resting BP - appropriate response. Chest Pain. sone. Arrhythmias: none. ST Changes: none. Overall	al Capacity; norm cisc normal rests one, ST Change	Function use to Exer	G norma BP Respo	Summary: Resting ECG: pormal. Fur Exercise: appropriate. BP Response to response. Cleat Pain mone. Arrhythm	Exercise:					rdering MD: Test Type:	Ref. MD: Ordering MD Technician: Test Type: Comment:	
2 04:00	Max. 51:-1.35 mm, 0.00 mV/s m III, EXERCISE STAGE 2 04:00 STHR mdex: 0.36 µV/bpm	B IIII, EXE	appm NV%	ex: 0.36 µV	STARR me					χ	Medical History	
me 07:06 of max predicted 188 bpm HR at rest: 130 BP at rest: 120/80 Max RPP: 25060 mmHg*bpm 10 METS	188 bpm HR at 0 Max RPP: 25	:06 predicted cst: 129/% S	e Time 07	BRUCE: Total Exercise Time 07:06 Max HR: 193 bpm 102% of max predicted 188 bpm Max BP: 150/80 mmHg BP at rest; 120/80 Max R Maximum Workload: 10.10 METS	BRUCE I Max HR: Max BP: I					m 58 kg	tion fail and	15.11.2024 4:35:02pm
ASIAN HOSPITAL											3	Patient ID 03382



Age/Gender : 32 Yrs/Female

Ref. Dr. : MEDIWHEEL

Report Date : 15/11/2024



HAEMATOLOGY REPORT

Test Description Result Unit Biological Reference Range

BLOOD GROUP AND RH FACTOR

Blood Group 'O'

Rh Factor POSITIVE(+VE)





SPL24/10098

Age/Gender : 32 Yrs/Female Ref. Dr. : MEDIWHEEL Report Date : 15/11/2024



HBA1C/GLYCOCYLATED

HbA1c Glycosilated Haemoglobin

Method: HPLC, NGSP certified

Estimated Average Glucose:

103

5.2

mg/dL

%

As per American Diabetes Association (ADA)					
Reference Group	HbA1c in %				
Non diabetic adults >=18 years	<5.7				
At risk (Prediabetes)	5.7 - 6.4				
Diagnosing Diabetes	>= 6.5				
Therapeutic goals for glycemic control	Age > 19 years Goal of therapy: < 7.0 Action suggested: > 8.0 Age < 19 years Goal of therapy: <7.5				

ADA	ADA criteria for correlation					
HbA1c(%)	Mean Plasma Glucose (mg/dL)					
6	126					
7	154					
8	183					
9	212					
10	240					
11	269					
12	298					

Note:1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled .

2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments:HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.





Age/Gender : 32 Yrs/Female

Ref. Dr. : MEDIWHEEL



Report Date : 15/11/2024



BIOCHEMISTRY REPORT

Test Description	Result	Unit	Biological Reference Range
LIPID PROFILE	-	-	
Cholesterol-Total Method: CHOD/PAP	147	mg/dL	< 200 : Desirable 200-239 : Borderline risk > 240 : High risk
Triglycerides level Method: Lipase / Glycerol Kinase)	93	mg/dL	< 150 : Normal 150–199 : Borderline-High 200–499 : High > 500 : Very High
HDL Cholesterol Method: CHOD/PAP	36	mg/dL	< 40 : Low 40 - 60 : Optimal > 60 : Desirable
LDL Cholesterol Method: Homogeneous enzymatic end point assay	92.40	mg/dL	< 100 : Normal 100 - 129 : Desirable 130 – 159 : Borderline-High 160 – 189 : High > 190 : Very High
VLDL Cholesterol Method: Calculation	18.60	mg/dL	7 - 40
CHOL/HDL RATIO Method: Calculation	4.08	Ratio	3.5 - 5.0
LDL/HDL RATIO Method: Calculation	2.57	Ratio	0 - 3.5

Metriou. Calculation	
Interpretation	
Lipid profile can measure the amount	of Total cholesterol's and triglycerides in blood:
Test	Comment
Total cholesterol:	measures all the cholesterol in all the lipoprotein particles
High-density lipoprotein cholesterol (HDL-C):	measures the cholesterol in HDL particles; often called "good cholesterol" because HDL-C takes up excess cholesterol and carries it to the liver for removal.
Low-density lipoprotein cholesterol (LDL-C):	measures the cholesterol in LDL particles; often called "bad cholesterol" because it deposits excess cholesterol in walls of blood vessels, which can contribute to atherosclerosis
Triglycerides:	measures all the triglycerides in all the lipoprotein particles; most is in the very low-density lipoproteins (VLDL).





Age/Gender : 32 Yrs/Female

Ref. Dr. : MEDIWHEEL : 15/11/2024 Report Date



BIOCHEMISTRY REPORT

Test Description	Result	Unit	Biological Reference Range
BLOOD SUGAR FASTING & PP (BSI	F & PP)		
BLOOD SUGAR FASTING Method: Hexokinase	82	mg/dl	
Fasting Urine Sugar	Absent		
BLOOD SUGAR POST PRANDIAL Method: Hexokinase	126	mg/dl	
Postprandial Urine Sugar ADA 2019 Guidelines for diagnosis of Di	Absent		

Fasting Plasma Glucose > 126 mg/dl Postprandial Blood Glucose > 200 mg/dl Random Blood Glucose > 200 mg/dl HbA1c Level > 6.5%





: 32 Yrs/Female

Ref. Dr. : MEDIWHEEL

Age/Gender

Report Date : 15/11/2024



BIOCHEMISTRY REPORT

Test Description	Result	Unit	Biological Reference Range
Serum Creatinine Method: Modified Jaffe's	0.7	mg/dL	0.60 - 1.40
LIVER FUNCTION TEST (LFT)			
TOTAL BILIRUBIN	0.75	mg/dl	0.3 - 1.2
Method: Serum, Jendrassik Grof			
DIRECT BILIRUBIN	0.22	mg/dL	0.0 - 0.3
Method: Serum, Diazotization			
INDIRECT BILIRUBIN	0.53	mg/dl	0.3 - 1.0
Method: Serum, Calculated			
SGPT (ALT)	26	U/L	15 - 40
Method: Serum, UV with P5P, IFCC 37 degree			
SGOT (AST)	22	U/L	15 - 40
Method: Serum, UV with P5P, IFCC 37 degree			
ALKALINE PHOSPHATASE	82	U/L	33 - 98
Method: DGKC			
TOTAL PROTEIN	6.6	g/dl	6.0 - 8.0
Method: Serum, Biuret, reagent blank end point			
SERUM ALBUMIN	3.7	g/dl	3.5 - 5.2
Method: Serum, Bromocresol green			
SERUM GLOBULIN	2.90	g/dl	1.8 - 3.6
Method: Serum, Calculated			
A/G RATIO	1.28		1.2 - 2.2
Method: Serum, Calculated			
Gamma Glutamyl Transferase-Serum	19	IU/L	12 - 43
Method: Kinetic			

NOTE:

In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or Non alcoholic fatty liver disease, Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.





SPL24/10098

Age/Gender : 32 Yrs/Female Ref. Dr. : MEDIWHEEL Report Date : 15/11/2024



BUN 11 mg/dl 7 - 21

Method: Calculated Clinical Significance:

Urea Nitrogen (BUN) - Urea is the principle waste product of protein catabolism. BUN is most commonly measured in the diagnosis and treatment of certain renal and metabolic diseases. Increased BUN concentration may result from increased production of urea due to

(1) diet or excessive destruction of cellular proteins as occurs in massive infection and fevers,

(2) reduced renal perfusion resulting from dehydration or heart failure,

(3) nearly all types of kidney disease, and

(4) mechanical obstruction to urine excretion such as is caused by stones, tumors, infection, or stricture. Decreased urea levels are less frequent and occur primarily in advanced liver disease and in overhydration.





Age/Gender : 32 Yrs/Female Ref. Dr. : MEDIWHEEL

Report Date : 15/11/2024



IMMUNOASSAY REPORT

Test Description	Result	Unit	Biological Reference Range
rest Bescription	- Ticount		
Thyroid Function Test (TFT)			
Т3	134	ng/dl	80-253 : 1 Yr-10 Yr,
		_	76-199 : 11 Yr-15 Yr,
			69-201 :16 Yr-18 Yr,
			87-173 : > 18 years,
Т4	9.96	ng/dl	5.9-21.5 :10-31 Days,
		_	5.9-21.5 :0-1 Month,
			6.4-13.9 :2-12 Months,
			6.09-12.23 :>1 Yr
TSH(Serum)	3.69	ng/dl	0.52-16.0 :1 Day - 30 Days
		· ·	0.55-7.10 :1 Mon-5 Years
			0.37-6.00 :6 Yrs-18 Years
			0.38-5.33 :18 Yrs-88 Years
			0.50-8.90 :88 Years

Method: ECLIA

Clinical features of thyroid disease				
Hypothyroidism	Hyperthyroidism	Grave's disease		
Lethargy	Tachycardia	Exophthalmos/proptosis		
Weight gain	Palpitations (atrial fibrillation)	Chemosis		
Cold intolerance	Hyperactivity	Diffuse symmetrical goitre		
Constipation	Weight loss with increased appetite	Pretibial myxoedema (rare)		
Hair loss	Heat intolerance	Other autoimmune conditions		
Dry skin	Sweating			
Depression	Diarrhoea			
Bradycardia	Fine tremor			
Memory impairment	Hyper-reflexia			
Menorrhagia	Goitre			
	Palmar erythema			
	Onycholysis			
	Muscle weakness and wasting			
	Oligomenorrhea/amenorrhoea			





: 32 Yrs/Female

Ref. Dr. : MEDIWHEEL

Report Date : 15/11/2024



URINE EXAMINATION REPORT

Test Description	Result	Unit	Biological Reference Range
•	-		·

URINE ROUTINE

Age/Gender

Physical Examination

Colour Pale Yellow Pale Yellow

Apperance Clear Clear

Reaction Acidic
Deposit Absent

Chemical Examination

Specific Gravity 1.005 Albumin Absent

Sugar NIL Absent

Acetone Absent

Bile Salt Absent Absent Bile Pigment Absent Absent

Microscopic Examination

NIL /hpf Nil RBC's 1-2/hpf /hpf 2-3/hpf Pus cells NIL 1-2/hpf **Epithelial Cells** /hpf Absent Absent Crystals Not Seen Not Seen Casts **Absent Absent Amorphous Deposit**





Age/Gender : 32 Yrs/Female Ref. Dr. : MEDIWHEEL

Report Date : 15/11/2024



Test Description	Result	Unit	Biological Reference Range
COMPLETE BLOOD COUNT			
Total WBC Count	6400	cell/cu.mm	4000 - 11000
Haemoglobin	12.3	g%	11 - 16
Platelet Count	289000	/cumm	150000 - 450000
RBC Count	4.18	/Mill/ul	3.50 - 5.50
RBC INDICES			
Mean Corp Volume MCV	85.2	fL	80 - 97
Mean Corp Hb MCH	29.4	pg	26 - 32
Mean Corp Hb Conc MCHC	34.6	gm/dL	31.0 - 36.0
Hematocrit HCT	35.6	%	36.0 - 48.0
RDW-CV	12.1	%	11.6 - 14.0
RDW-SD	33.6	fL	37.0 - 54.0
DIFFERENTIAL LEUCOCYTE CO	UNT		
Neutrophils	60	%	40 - 75
Lymphocytes	32	%	20 - 45
Monocytes	04	%	02 - 10
Eosinophils	04	%	01 - 06
Basophils	00	%	00 - 01

^{1.} As per the recommendation of International council for Standardization in Hematology, the differential leukocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood.

ESR 09 mm/hr Male: 0-8 mm at 1 Hr.

Female: 0-20 mm at 1 Hr.

INTERPRETATION:

- 1. It indicates presence and intensity of an inflammatory process, never diagnostic of a specific disease. Changes are more significant than a single abnormal test.
- 2. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, bacterial endocarditis, acute rheumatic fever, rheumatoid arthritis, SLE, Hodgkins disease, temporal arteritis, polymyalgia rheumatica.
- 3. It is also increased in pregnancy, multiple myeloma, menstruation, and hypothyroidism.



^{2.} Test conducted on EDTA whole blood.



Age/Gender : 32 Yrs/Female Ref. Dr. : MEDIWHEEL

Report Date : 15/11/2024



